Publications

Zaiss DMW, Pearce EJ, Artis D, McKenzie ANJ, Klose CSN.  2024.  Cooperation of ILC2s and TH2 cells in the expulsion of intestinal helminth parasites.. Nat Rev Immunol. 24(4):294-302.

Ahmed A, Joseph AM, Zhou J, Horn V, Uddin J, Lyu M, Goc J, Sockolow RE, Wing JB, Vivier E et al..  2024.  CTLA-4-expressing ILC3s restrain interleukin-23-mediated inflammation.. Nature. 630(8018):976-983.

Arifuzzaman M, Won THyung, Yano H, Uddin J, Emanuel ER, Hu E, Zhang W, Li T-T, Jin W-B, Grier A et al..  2024.  Dietary fiber is a critical determinant of pathologic ILC2 responses and intestinal inflammation.. J Exp Med. 221(5)

Kim B, Rothenberg ME, Sun X, Bachert C, Artis D, Zaheer R, Deniz Y, Rowe P, Cyr S.  2024.  Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases.. J Allergy Clin Immunol. 153(4):879-893.

Zhang W, Artis D.  2024.  Stressing out the intestinal microbiota via a brain-neuroglandular circuit.. Cell Res.

Li Z, Ma R, Tang H, Guo J, Shah Z, Zhang J, Liu N, Cao S, Marcucci G, Artis D et al..  2024.  Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death.. Cell. 187(3):624-641.e23.

Feng X, Andersson T, Gschwend J, Flüchter P, Berest I, Muff JL, Carchidi D, Lechner A, de Tenorio JC, Brander N et al..  2024.  Tuft cell IL-17RB restrains IL-25 bioavailability and reveals context-dependent ILC2 hypoproliferation.. bioRxiv.

Won THyung, Arifuzzaman M, Parkhurst CN, Miranda IC, Zhang B, Hu E, Kashyap S, Letourneau J, Jin W-B, Fu Y et al..  2025.  Host metabolism balances microbial regulation of bile acid signalling.. Nature. 638(8049):216-224.

Amisaki M, Zebboudj A, Yano H, Zhang SLinsey, Payne G, Chandra AKaya, Yu R, Guasp P, Sethna ZM, Ohmoto A et al..  2025.  IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer.. Nature.

Amisaki M, Zebboudj A, Yano H, Zhang SLinsey, Payne G, Chandra AKaya, Yu R, Guasp P, Sethna ZM, Ohmoto A et al..  2025.  IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer.. Nature.

Amisaki M, Zebboudj A, Yano H, Zhang SLinsey, Payne G, Chandra AKaya, Yu R, Guasp P, Sethna ZM, Ohmoto A et al..  2025.  IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer.. Nature.